Advertisement

Electrocardiographic Screening in Children With Attention-Deficit Hyperactivity Disorder

      Some investigators have suggested that children receiving stimulant medications to manage attention-deficit hyperactivity disorder should undergo screening electrocardiography to identify asymptomatic cardiac disease. However, no study to date has examined the efficacy and costs of this strategy. In the present study we sought to determine the utility of electrocardiographic screening in children with attention-deficit hyperactivity disorder. We reviewed the clinical experience of electrocardiographic screening of subjects with attention-deficit hyperactivity disorder <21 years of age from April to September 2008. Additional cardiac care and testing that resulted from an abnormal initial electrocardiogram were recorded. Screening electrocardiograms were obtained in 1,470 children with attention-deficit hyperactivity disorder and were interpreted as abnormal in 119 subjects (8.1%). Further evaluation of these 119 subjects included 63 transthoracic echocardiograms, 5 stress tests, and 9 Holter monitor studies. Cardiac disease was identified in 5 subjects (0.3% of entire cohort), yielding a positive predictive value of 4.2%. Cardiac diagnoses included ventricular pre-excitation syndrome (n = 2), bicuspid aortic valve (n = 2), and moderate secundum atrial septal defect (n = 1). The mean cost of electrocardiographic screening including further testing for subjects with abnormal initial screen results was $58 per child. The mean cost to identify a true-positive result was $17,162. In conclusion, electrocardiographic screening for children with attention-deficit hyperactivity disorder can successfully identify cardiac disease in otherwise asymptomatic subjects, although the positive predictive value is low. Ongoing studies are needed to know what role electrocardiographic screening should play in the management of children with attention-deficit hyperactivity disorder.
      To read this article in full you will need to make a payment

      References

        • Vetter V.L.
        • Elia J.
        • Erickson C.
        • Berger S.
        • Blum N.
        • Uzark K.
        • Webb C.L.
        Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
        Circulation. 2008; 117: 2407-2423
        • 2008 Medicare physician fee schedule
        (Accessed October 10, 2008.)
        • U.S. Department of Labor, Bureau of Labor Statistics
        Employment and earnings, 2007 annual averages and the monthly labor review.
        (Accessed November 1, 2007)
        • Perrin J.M.
        • Friedman R.A.
        • Knilans T.K.
        Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
        Pediatrics. 2008; 122: 451-453
        • Pelliccia A.
        • Culasso F.
        • Di Paolo F.M.
        • Accettura D.
        • Cantore R.
        • Castagna W.
        • Ciacciarelli A.
        • Costini G.
        • Cuffari B.
        • Drago E.
        • Federici V.
        • Gribaudo C.G.
        • Iacovelli G.
        • Landolfi L.
        • Menichetti G.
        • Atzeni U.O.
        • Parisi A.
        • Pizzi A.R.
        • Rosa M.
        • Santelli F.
        • Santilio F.
        • Vagnini A.
        • Casasco M.
        • Di L.L.
        Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening.
        Eur Heart J. 2007; 28: 2006-2010
        • Haneda N.
        • Mori C.
        • Nishio T.
        • Saito M.
        • Kajino Y.
        • Watanabe K.
        • Kijima Y.
        • Yamada K.
        Heart diseases discovered by mass screening in the schools of Shimane Prefecture over a period of 5 years.
        Jpn Circ J. 1986; 50: 1325-1329
      1. Garson A.J. Bricker J. Fisher D. Neish S. Electrocardiography in the Science and Practice of Pediatric Cardiology. Williams and Wilkins, Baltimore1998
        • Chiu C.C.
        • Hamilton R.M.
        • Gow R.M.
        • Kirsh J.A.
        • McCrindle B.W.
        Evaluation of computerized interpretation of the pediatric electrocardiogram.
        J Electrocardiol. 2007; 40: 139-143
        • Taggart N.W.
        • Haglund C.M.
        • Tester D.J.
        • Ackerman M.J.
        Diagnostic miscues in congenital long-QT syndrome.
        Circulation. 2007; 115: 2613-2620
      2. Health Canada suspends the market authorization of ADDERALL XR®, a drug prescribed for attention deficit hyperactivity disorder (ADHD) in children.
        (Accessed February 9, 2005.)
        • Gracious B.L.
        Atrioventricular nodal re-entrant tachycardia associated with stimulant treatment.
        J Child Adolesc Psychopharmacol. 1999; 9: 125-128
        • Lehnart S.E.
        • Ackerman M.J.
        • Benson Jr, D.W.
        • Brugada R.
        • Clancy C.E.
        • Donahue J.K.
        • George Jr, A.L.
        • Grant A.O.
        • Groft S.C.
        • January C.T.
        • Lathrop D.A.
        • Lederer W.J.
        • Makielski J.C.
        • Mohler P.J.
        • Moss A.
        • Nerbonne J.M.
        • Olson T.M.
        • Przywara D.A.
        • Towbin J.A.
        • Wang L.H.
        • Marks A.R.
        Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function.
        Circulation. 2007; 116: 2325-2345
        • Mayes R.
        • Bagwell C.
        • Erkulwater J.
        ADHD and the rise in stimulant use among children.
        Harv Rev Psychiatry. 2008; 16: 151-166
      Advertisement